Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression
Targeting the MDK/LRP1 axis with Resmetirom offers a promising therapeutic strategy for MASH-associated HCC, addressing both metabolic dysfunction and tumor progression.
Authors
- Jiu-Fu Lu (ORCID: https://orcid.org/0009-0006-2044-0750)
- Irene Oi-Lin NG
- Eva Lee
- Abdullah Husain (ORCID: https://orcid.org/0000-0003-0004-9974)
- Tina Suoangbaji
- Xin Zhang (ORCID: https://orcid.org/0000-0002-8582-1128)
- Daniel Ho (ORCID: https://orcid.org/0000-0001-8608-8426)
- Joyce Man-Fong Lee
- Lu Tian
- Karen Man-Fong Sze
- Charry Shuk-Ching Hui
- Huan Deng
- Yu‑Man Tsui
Institutions
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Hepatology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1097/hep.0000000000001675
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00